Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Ранг среди акций #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Цена акции
$28.53
Последняя синхронизация: 2026-08-27
Рыночная капитализация
$1.96B
Изменение (1 день)
-1.65%
Изменение (1 год)
106.14%
Страна
IE
Торговля GH Research PLC (GHRS)

Категория

Коэффициент P/B для GH Research PLC (GHRS)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций GH Research PLC, текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для GH Research PLC с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов
Компания P/B Разница P/B Страна
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH